February 2015, Volume 1, Issue 2

February 2015

Volume 1, Issue 2

This issue features ABIM’s update to MOC, the endocrinologist’s perspective on diabetes management, an analysis of the Choosing Wisely program, and more.

Table of Contents

February 2015

Letter From a Cleveland Jail to the ABIM: Redux

Sunday, February 1st, 2015
Dear American Board of Internal Medicine, Remember me? I’m the guy who sent those other letters to you over the past couple of years, in...

Managing the Diabetic Patient: The Endocrinologist’s Perspective

Sunday, February 1st, 2015
Where do the areas of hematology and endocrinology intersect in diabetes management? I have found that, in order to do the endocrinology work that I...

February 2015

Speaking Up for Hematology: Change Comes at ABIM After Years of ASH Advocacy

Sunday, February 1st, 2015
Since 2001, ASH has challenged the American Board of Internal Medicine (ABIM) on its Maintenance of Certification (MOC) program, citing a lack of evidence for the...

NIH Awards Several Grants for Deciphering Gene Regulation, and more

Sunday, February 1st, 2015
Multiple Researchers Awarded NIH Grants to Decipher the Language of Gene Regulation The National Institutes of Health has awarded multiple grants totaling more than $28 million aimed...

February 2015

Pulling Back the Curtain: Benjamin Ebert, MD, PhD

Sunday, February 1st, 2015
What was your first job?  In high school, I built up a little business for myself as a math tutor for kids of all ages...

Who Cares About What Patients Think? The FDA, Insurance Payers, Researchers… Maybe You Should...

Sunday, February 1st, 2015
While patient-reported outcomes (PROs) are nothing new in the field of medicine, they may now be newly appreciated. The U.S. Food and Drug Administration (FDA)...

February 2015

Choosing Wisely Across the Spectrum of Internal Medicine

Sunday, February 1st, 2015
The Choosing Wisely® campaign, an initiative of the American Board of Internal Medicine (ABIM) Foundation, encourages clinicians and patients to engage in conversations to reduce...

Should I have concerns about using an oral thrombin inhibitor in a patient with...

Sunday, February 1st, 2015
This month, Michael H. Kroll, MD, advises on switching a patient with a history of deep-vein thrombosis (DVT) from warfarin to an oral thrombin inhibitor.A...

What You Should Know About Sickle Cell Trait

Sunday, February 1st, 2015
Sickle cell trait (SCT) is not a mild form of sickle cell disease. Having SCT simply means that a person carries a single gene for sickle...

February 2015

Preventing Blood Clots without Increasing Bleeding Risk?

Sunday, February 1st, 2015
Clinicians treating patients with anticoagulants have to walk a fine line  in preventing blood clot formation while also minimizing bleeding risk. Targeting factor XI,...
WIB_icon

Ibritumomab Tiuxetan Ups Survival in Tough-to-Treat Diffuse Large B-Cell Lymphoma

Sunday, February 1st, 2015
Many patients with aggressive B-cell non-Hodgkin lymphoma (NHL) are cured of the disease after short-course chemotherapy and radiation. Certain adverse risk factors, though, make relapse more likely. Ibritumomab tiuxetan as add-on...
WIB_icon

Brentuximab Vedotin Active in Relapsed/Refractory B-Cell Lymphoma

Sunday, February 1st, 2015
For patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for transplant or fail to respond to salvage regimens, treatment with brentuximab...

A Zebrafish and Enhanced Imaging Captures How Blood Stem Cells Take Root

Sunday, February 1st, 2015
A research team from Boston Children Hospital’s Stem Cell Research Program has provided the first direct glimpse into how blood stem cells take root...

FDA Expands Use of Ibrutinib, Fast Track Designation Granted to SGX301, and more

Sunday, February 1st, 2015
FDA Expands Use  of Ibrutinib for Waldenström Macroglobulinemia The U.S. Food and Drug Administration (FDA) approved the expanded use of ibrutinib to treat Waldenström macroglobulinemia (WM),...

ELOQUENT-2, SUSTAIN, and more

Sunday, February 1st, 2015
LEUKEMIA Selected by David Steensma, MD Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (NCT02267278) Study Design: Open-label, single-group assignment safety/efficacy study Study Start Date: January 2015 ...

The Debate Rages on: Is Omitting Radiation Therapy from Hodgkin Lymphoma Good for Patients?

Sunday, February 1st, 2015
Although Hodgkin lymphoma (HL) is frequently treated with a combination of chemotherapy and radiation therapy, there is a movement towards omitting radiation therapy altogether....

Is It Time to Reconsider Allogeneic SCT in NPM1-Mutant AML?

Sunday, February 1st, 2015
Allogeneic stem cell transplantation (SCT) significantly improved rates of relapse-free survival (RFS), but not overall survival (OS) in patients with acute myeloid leukemia (AML)...
WIB_icon

Superficial Vein Thromboses Put People at Risk for Subsequent Blood Clots

Sunday, February 1st, 2015
Until recently, a superficial vein thrombosis (SVT) was seen as a painful induration of limited clinical significance. New evidence from a large population-based study...

February 2015

Treating VTE in Vulnerable Populations: What are the Options?

Sunday, February 1st, 2015
Over the last 20 years, there have been numerous advances in pharmacologic options for the treatment of venous thromboembolism (VTE), including low-molecular-weight heparins (LMWHs),...

For ASCT in Myeloma, Does One Size Fit All?

Sunday, February 1st, 2015
Over the last decade, drug development for multiple myeloma has reached an unprecedented pace, and has led to the expansion of regimens that now...

SHARE